Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• California Resources completes $63M acquisition of Crimson Midstream
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance